Stefan Schreiber, MD

A conclusion emphasizing the importance of translating clinical research into everyday practice and continuing innovation to improve patient quality of life and long-term outcomes.

Forward-looking perspectives on how predictive biomarkers, genetic profiling, and precision tools will guide individualized IBD management in the coming years.

Exploration of combination and sequencing strategies for patients with refractory or advanced disease to achieve comprehensive disease control.

Analysis of how to balance established therapies such as anti-TNFs and immunomodulators with novel agents like JAK inhibitors, S1P modulators, and IL-23 inhibitors.

Insight into how response patterns from major studies help identify optimal treatment timing and predict which patients benefit most from specific interventions.

A focused review of evidence showing that early initiation of biologic therapy leads to higher remission and healing rates compared to later-stage treatment.

Insight into how response patterns from major studies help identify optimal treatment timing and predict which patients benefit most from specific interventions.

Examination of how deeper healing correlates with improved long-term outcomes, emphasizing the translation of clinical trial findings into practical treatment adjustments.

An overview of the changing IBD treatment landscape, highlighting how deeper remission targets and emerging therapies are redefining patient care and treatment goals.

An overview of the changing IBD treatment landscape, highlighting how deeper remission targets and emerging therapies are redefining patient care and treatment goals.